TITLE

Points from Letters: Launching of New Drugs

AUTHOR(S)
Carne, H. J.; Dell, A. J.; Mitchell, Diana; Andrews, Margaret Scott; Swirsky, S.
PUB. DATE
January 1974
SOURCE
British Medical Journal;1/26/1974, Vol. 1 Issue 5899, p162
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
No abstract available.
ACCESSION #
64109459

 

Related Articles

  • PRODUCT BRIEFS.  // Medical Device Daily;12/26/2013, Vol. 17 Issue 248, p5 

    The article offers U.S. medical device industry news briefs, a complete response letter received by the subsidiary of Actavis PLC from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) and the launch of a sample prep workflow for single-cell DNA sequencing by Fluidigm.

  • WellPoint to unveil Medicare Part D decision tool. Kibbe, Cindy // New Hampshire Business Review;10/27/2006, Vol. 28 Issue 23, p38 

    The article reports on the launch of a Web-based decision tool from the health insurance company WellPoint Inc. for its drug benefit plan called Medicare Part D in New Hampshire. Joan E. Herman, the president and CEO of WellPoint, believes that the tool will provide seniors in findings an...

  • NEWS: Pipeline.  // Medical Marketing & Media;Oct2007, Vol. 42 Issue 10, p10 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Abbreviated New Drug Application for phentermine of Caraco Pharmaceutical Laboratories Ltd. has been granted approval by the U.S. Food and Drug Administration (FDA). Quinnova Pharmaceuticals has launched its...

  • Pfizer pushes back amid Chantix safety worries. Arnold, Matthew // Medical Marketing & Media;Jul2008, Vol. 43 Issue 7, p8 

    The article reports that Pfizer Inc. has published a full page advertisement in national newspapers to fight back the bad press related to side effects of the drug Chantix. The advertisement appeared as an open letter from Pfizer chief medical officer Joseph Feczko emphasizing the risk/benefit...

  • Welcome to our new editorial, op-ed pages. Mantius, Peter // Long Island Business News (7/1993 to 5/2009);04/27/2001, Vol. 48 Issue 17, p58A 

    Comments on the launching of another version of editorial and op-ed pages of the Long Island Business News in New York. Promotion of animated discussion on business-related issues; Presentation of feedback by guest commentaries and letters to the editor; Attraction of page to the variety of...

  • Guiding drug discovery through 2003.  // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p3 

    With the fall in the numbers of new drugs reaching crisis point, there has never been a better time to stop and consider how best to run the drug pipeline. This year we launch two new sections with the aim of helping us to understand the craft of drug discovery.

  • JURILAB LAUNCHES NEW DRUG METABOLISM ENZYME TEST.  // Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p1 

    Reports on the launch of a new drug metabolism enzyme test from Jurilab Ltd., as of September 2003.

  • Temporary stents reach NZ market. McMillan, Virginia // New Zealand Doctor;11/21/2012, p13 

    The article reports on the launch of the absorbable metallic drug-eluting stents from Abbot in the New Zealand market.

  • FDA Seeks More Data on Iluvien Studies.  // Review of Ophthalmology;Feb2011, Vol. 18 Issue 2, p7 

    The article reports on the Complete Response Letter (CRL) received by Alimera Sciences Inc. from the U.S. Food and Drug Administration regarding Alimera's New Drug Application for the investigational drug Iluvien.

  • Coagulopathies from drugs2. Nederlof, P. // British Dental Journal;3/27/2004, Vol. 196 Issue 6, p311 

    Presents a letter to the editor about coagulopathies from drugs.

Share

Read the Article

Other Topics